Porton USA

About Porton USA

Founded in 2005, Porton Pharma Solutions Ltd. is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide customer development and manufacturing services for small molecule APIs, TIDES, Biologics and Gene & Cell Therapies from pre-clinical to commercialization. A Customer-Centric, Innovative, and Reliable CDMO with Global Solutions.

  • US
  • 2022
    On CPHI since
  • 5000+
    Employees
Company types
CMO/CDMO
Contact info
  • 6 Cedarbrook Dr, Cranbury, NJ 08512 USA, 08512, Cranbury, New Jersey, United States
Meet us at

CPHI North America 2024

Pennsylvania Convention Center, Philadelphia
07 May 2024 - 09 May 2024

Porton USA Resources (2)

  • Webinar Co-processing: A Multifaceted Approach for Enhancing Density & Powder Flow

    Discover the Power of Co-processing: Unleashing the Potential of Pharmaceutical Manufacturing. Our multifaceted co-processing technology is a game-changer, boosting density, optimizing powder flow, ensuring content uniformity, and enhancing solubility-dissolution. But that's not all – it also goes above and beyond, safeguarding your workforce from potent Active Pharmaceutical Ingredients (APIs). Embrace innovation and efficiency with our cutting-edge co-processing solutions and elevate your pharmaceutical production to new heights. Experience the future of manufacturing! Understand the potential of co-processing technology - what are the key benefits over existing solutions? Discover how the industry is embracing co-processing technology Learn some of the common techniques on the co-processing technology platform See examples of how co-processing can improve powder flow and density, and improve formulation rigidity
  • Webinar Chiral Resolution by Salt/Cocrystal Formation

    Most of the drug molecules are chiral compounds with enantiomers. Each enantiomer may show significant differences in biological activities, such as pharmacodynamics, pharmacokinetics and toxicity. It is therefore recommended to market chiral drugs containing only the desired enantiomer. It is thus critical to develop a production process that leads to enantiopure dug substance. In this context, chiral resolution has become a crucial step in pharmaceutical development and crystallization-based resolutions are widely utilized to produce enantiopure drug substance of high purity. This presentation will review the concept of conglomerate, racemic compound and solid solution as well as how to differentiate them using phase diagrams and analytical techniques. It will discuss chiral resolution methods though salt and cocrystal formation followed by crystallization using a couple of case studies. One case study was to identify a cocrystal conglomerate followed by development of a chiral resolution process based on preferred crystallization. The other case study is to perform classic chiral resolution by diastereomeric salt formation which is considered one of the most effective methods for production of chirally pure drugs at large scale. Understand why classical resolution by salt formation is often considered as one of the most efficient methods to produce enantiopure pharmaceuticals on a large scale strategically design a rational approach to a solid form screening study Optimize a crystallization process to be scaled up to various scales